Clinical trial
Phase 1b Study of TMV Vaccine Therapy Alone and TMV Vaccine Plus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT06868433 is registered in ClinicalTrials.gov with Emory University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1b Study of TMV Vaccine Therapy Alone and TMV Vaccine Plus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Lead sponsor
- Emory University
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- May 8, 2025
- Completion date
- December 31, 2028
- Enrollment
- 40 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage iv hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, metastatic head and neck squamous cell carcinoma, metastatic hypopharyngeal squamous cell carcinoma, metastatic laryngeal squamous cell carcinoma, metastatic nasopharyngeal squamous cell carcinoma, metastatic oral cavity squamous cell carcinoma, metastatic oropharyngeal squamous cell carcinoma, metastatic sinonasal squamous cell carcinoma, recurrent head and neck squamous cell carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent nasopharyngeal squamous cell carcinoma, recurrent oral cavity squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, recurrent sinonasal squamous cell carcinoma, squamous cell carcinoma of unknown primary, stage iv cutaneous squamous cell carcinoma of the head and neck ajcc v8, stage iv hypopharyngeal carcinoma ajcc v8, stage iv laryngeal cancer ajcc v8, stage iv lip and oral cavity cancer ajcc v8, stage iv nasopharyngeal carcinoma ajcc v8, stage iv oropharyngeal (p16-negative) carcinoma ajcc v8, stage iv sinonasal cancer ajcc v8